Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00246-024-03692-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amblyopia screening: the current state and opportunities for optimization.
Expert Rev Med Devices
January 2025
Division of Ophthalmology, Children's Hospital of Philadelphia.
Introduction: Amblyopia, the leading cause of monocular childhood vision loss, affects millions and is projected to increase. Early detection and treatment are crucial for preventing vision impairment.
Areas Covered: This commentary reviews the current state and opportunities for improvement in amblyopia screening strategy and technology focused primarily within the United States.
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.
Eur Respir J
January 2025
Assistance Publique Hôpitaux Paris (AP-HP), Hôpital Bichat, Département de Médecine Interne, Paris, France
Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification.
Front Immunol
December 2024
Department of Rehabilitation or Nursing, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Alzheimer's disease prediction and prevention in a public health perspective: Ethical considerations and collaborations beyond the biomedical paradigm.
J Alzheimers Dis
December 2024
Department of Health, Ethics and Society, Mental Health and Neuroscience Research Institute, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.
The prevention of dementia is increasingly a task for public health promotion and aims at the general public. This likewise holds for potentially modifiable lifestyle risk factors and biomarkers indicating susceptibility. This commentary argues that from a public health ethical perspective, there is a significant overlap between the implications and requirements of the biomedical domain and lifestyle approaches.
View Article and Find Full Text PDFReply letter to the commentary on "Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study".
Int J Surg
December 2024
Breast Disease Department, Weifang People's Hospital, The First Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!